Nectero Therapeutics

Nectero Therapeutics is a clinical-stage biotech company based in Tempe, Arizona, dedicated to transforming the treatment of aneurysmal disease. We are pioneering novel therapies, specifically the Nectero EAST ® System, to stabilize growth and prevent rupture of small to mid-sized abdominal aortic aneurysms (AAA). Our approach utilizes an endovascular technique to deliver a proprietary mixture, minimizing the need for major intervention like EVAR or open surgery. Led by a highly accomplished, multidisciplinary management team and supported by renowned physician leaders, Nectero Therapeutics is committed to improving patient outcomes and extending lives.

The Nectero EAST ® System offers a promising alternative for patients with AAAs that may not otherwise qualify for traditional treatment options. By strengthening the aortic tissue around the aneurysm, we aim to significantly delay or prevent the need for invasive procedures. We are focused on developing innovative solutions to address a significant public health concern.

Nectero Medical, Inc. (DBA Nectero Therapeutics) is at the forefront of this research, driven by a passion for advancing vascular medicine and providing hope for patients and their families. We are dedicated to rigorous clinical development and regulatory compliance, ensuring the safety and efficacy of our therapies.